Eighty percent (80%) of women aged 40-65 years reported having vasomotor menopausal symptoms (VMS) according to a survey of 4,754 women published in Menopause, The Journal of The North American Menopause Society. Vasomotor menopausal symptoms include hot flashes and night sweats or cold sweats. Insomnia, irritability, and trouble concentrating are additional symptoms often cited by patients.

Fifty-five percent (55%) of the surveyed women reported their vasomotor symptoms as moderate to severe, and more than half of these women were untreated. VMS has a substantial negative impact on women’s personal and professional lives, which increases with the severity of symptoms.

While hormone therapy is still widely used to treat VMS, there continue to be concerns about risks of venous thromboembolism, stroke, and breast cancer. According to the women surveyed, ~35% were hormone therapy-contraindicated and ~50% were hormone-therapy cautious or averse.

Have you seen similar statistics in your practice? What have you found to be successful in treating VMS with patients who are HRT-contraindicated or averse?

Eighty percent (80%) of women aged 40-65 years reported having vasomotor menopausal symptoms (VMS) according to a survey of 4,754 women published in Menopause, The Journal of The North American Menopause Society. Vasomotor menopausal symptoms include hot flashes and night sweats or cold sweats. Insomnia, irritability, and trouble concentrating are additional symptoms often cited by patients.

Fifty-five percent (55%) of the surveyed women reported their vasomotor symptoms as moderate to severe, and more than half of these women were untreated. VMS has a substantial negative impact on women’s personal and professional lives, which increases with the severity of symptoms.

While hormone therapy is still widely used to treat VMS, there continue to be concerns about risks of venous thromboembolism, stroke, and breast cancer. According to the women surveyed, ~35% were hormone therapy-contraindicated and ~50% were hormone-therapy cautious or averse.

Have you seen similar statistics in your practice? What have you found to be successful in treating VMS with patients who are HRT-contraindicated or averse?

Eighty percent (80%) of women aged 40-65 years reported having vasomotor menopausal symptoms (VMS) according to a survey of 4,754 women published in Menopause, The Journal of The North American Menopause Society. Vasomotor menopausal symptoms include hot flashes and night sweats or cold sweats. Insomnia, irritability, and trouble concentrating are additional symptoms often cited by patients.

Fifty-five percent (55%) of the surveyed women reported their vasomotor symptoms as moderate to severe, and more than half of these women were untreated. VMS has a substantial negative impact on women’s personal and professional lives, which increases with the severity of symptoms.

While hormone therapy is still widely used to treat VMS, there continue to be concerns about risks of venous thromboembolism, stroke, and breast cancer. According to the women surveyed, ~35% were hormone therapy-contraindicated and ~50% were hormone-therapy cautious or averse.

Have you seen similar statistics in your practice? What have you found to be successful in treating VMS with patients who are HRT-contraindicated or averse?

This year’s North American Menopause Society (NAMS) four-day annual meeting is being held at the Hyatt Regency in Atlanta from Oct. 12 to 15, 2022. The theme of this year’s meeting is Menopause Science and Care—An Inclusive Perspective.

The mission of NAMS is to promote health and quality of life for women during midlife and beyond through an understanding of menopause and healthy aging. Members include obstetricians-gynecologists, primary care practitioners, nurse practitioners, and physician assistants. Click above for a detailed preview of the event.

This year’s North American Menopause Society (NAMS) four-day annual meeting is being held at the Hyatt Regency in Atlanta from Oct. 12 to 15, 2022. The theme of this year’s meeting is Menopause Science and Care—An Inclusive Perspective.

The mission of NAMS is to promote health and quality of life for women during midlife and beyond through an understanding of menopause and healthy aging. Members include obstetricians-gynecologists, primary care practitioners, nurse practitioners, and physician assistants. Click above for a detailed preview of the event.

This year’s North American Menopause Society (NAMS) four-day annual meeting is being held at the Hyatt Regency in Atlanta from Oct. 12 to 15, 2022. The theme of this year’s meeting is Menopause Science and Care—An Inclusive Perspective.

The mission of NAMS is to promote health and quality of life for women during midlife and beyond through an understanding of menopause and healthy aging. Members include obstetricians-gynecologists, primary care practitioners, nurse practitioners, and physician assistants. Click above for a detailed preview of the event.

This year’s North American Menopause Society (NAMS) four-day annual meeting is being held at the Hyatt Regency in Atlanta from Oct. 12 to 15, 2022. The theme of this year’s meeting is Menopause Science and Care—An Inclusive Perspective.

The mission of NAMS is to promote health and quality of life for women during midlife and beyond through an understanding of menopause and healthy aging. Members include obstetricians-gynecologists, primary care practitioners, nurse practitioners, and physician assistants. Click above for a detailed preview of the event.